Cargando…

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection

BACKGROUND: Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favora...

Descripción completa

Detalles Bibliográficos
Autores principales: Jo, Jungmin, Yoon, Dok Hyun, Lee, Sang Wook, Park, Chan-Sik, Huh, Jooryung, Lee, Kyoungmin, Kang, Eun Hee, Kim, Shin, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090332/
https://www.ncbi.nlm.nih.gov/pubmed/25025013
http://dx.doi.org/10.5045/br.2014.49.2.115
_version_ 1782480613352144896
author Jo, Jungmin
Yoon, Dok Hyun
Lee, Sang Wook
Park, Chan-Sik
Huh, Jooryung
Lee, Kyoungmin
Kang, Eun Hee
Kim, Shin
Suh, Cheolwon
author_facet Jo, Jungmin
Yoon, Dok Hyun
Lee, Sang Wook
Park, Chan-Sik
Huh, Jooryung
Lee, Kyoungmin
Kang, Eun Hee
Kim, Shin
Suh, Cheolwon
author_sort Jo, Jungmin
collection PubMed
description BACKGROUND: Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favorable outcomes, even after abbreviated chemotherapy of only 2 or 3 cycles. We investigated the effectiveness of abbreviated chemotherapy in patients with LS DLBCL after complete tumor resection. METHODS: We retrospectively reviewed 18 patients with LS DLBCL who underwent complete tumor resection followed by either 3 or 4 cycles of chemotherapy between March 2002 and May 2010. RESULTS: With a median follow-up period of 57.9 months (range, 31.8-130.2 months), no patients experienced disease relapse or progression; however, 1 patient experienced secondary acute myeloid leukemia during follow-up. The 5-year progression-free survival rate and overall survival rate were 93.3% and 94.1%, respectively. CONCLUSION: These results warrant further investigation into abbreviated chemotherapy as an alternative treatment for patients who have undergone complete resection of LS DLBCL.
format Online
Article
Text
id pubmed-4090332
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
record_format MEDLINE/PubMed
spelling pubmed-40903322014-07-14 Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection Jo, Jungmin Yoon, Dok Hyun Lee, Sang Wook Park, Chan-Sik Huh, Jooryung Lee, Kyoungmin Kang, Eun Hee Kim, Shin Suh, Cheolwon Blood Res Original Article BACKGROUND: Abbreviated chemotherapy followed by radiotherapy or full cycles of chemotherapy is recommended as a standard treatment for limited-stage (LS) diffuse large B-cell lymphoma (DLBCL). After complete resection of tumors, however, Burkitt and childhood B-cell Non-Hodgkin lymphoma show favorable outcomes, even after abbreviated chemotherapy of only 2 or 3 cycles. We investigated the effectiveness of abbreviated chemotherapy in patients with LS DLBCL after complete tumor resection. METHODS: We retrospectively reviewed 18 patients with LS DLBCL who underwent complete tumor resection followed by either 3 or 4 cycles of chemotherapy between March 2002 and May 2010. RESULTS: With a median follow-up period of 57.9 months (range, 31.8-130.2 months), no patients experienced disease relapse or progression; however, 1 patient experienced secondary acute myeloid leukemia during follow-up. The 5-year progression-free survival rate and overall survival rate were 93.3% and 94.1%, respectively. CONCLUSION: These results warrant further investigation into abbreviated chemotherapy as an alternative treatment for patients who have undergone complete resection of LS DLBCL. Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2014-06 2014-06-25 /pmc/articles/PMC4090332/ /pubmed/25025013 http://dx.doi.org/10.5045/br.2014.49.2.115 Text en © 2014 Korean Society of Hematology http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jo, Jungmin
Yoon, Dok Hyun
Lee, Sang Wook
Park, Chan-Sik
Huh, Jooryung
Lee, Kyoungmin
Kang, Eun Hee
Kim, Shin
Suh, Cheolwon
Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
title Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
title_full Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
title_fullStr Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
title_full_unstemmed Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
title_short Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
title_sort abbreviated chemotherapy for limited-stage diffuse large b-cell lymphoma after complete resection
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090332/
https://www.ncbi.nlm.nih.gov/pubmed/25025013
http://dx.doi.org/10.5045/br.2014.49.2.115
work_keys_str_mv AT jojungmin abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection
AT yoondokhyun abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection
AT leesangwook abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection
AT parkchansik abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection
AT huhjooryung abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection
AT leekyoungmin abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection
AT kangeunhee abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection
AT kimshin abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection
AT suhcheolwon abbreviatedchemotherapyforlimitedstagediffuselargebcelllymphomaaftercompleteresection